Reversal of Pathological Cardiac Hypertrophy via the MEF2-coregulator Interface

JCI insight - United States
doi 10.1172/jci.insight.91068
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Society for Clinical Investigation

Related search

Tripartite Motif 32 Prevents Pathological Cardiac Hypertrophy

Clinical Science
Medicine
2016English

Nuclear GAPDH Signaling Mediates Pathological Cardiac Hypertrophy

2019English

The Transcription Factor GATA-6 Regulates Pathological Cardiac Hypertrophy

Circulation Research
Cardiovascular MedicinePhysiologyCardiology
2010English

CaM Kinase Signaling Induces Cardiac Hypertrophy and Activates the MEF2 Transcription Factor in Vivo

Journal of Clinical Investigation
Medicine
2000English

The H3K9 Dimethyltransferases EHMT1/2 Protect Against Pathological Cardiac Hypertrophy

Journal of Clinical Investigation
Medicine
2016English

Mechanisms for the Transition From Physiological to Pathological Cardiac Hypertrophy

Canadian Journal of Physiology and Pharmacology
MedicinePhysiologyPharmacology
2020English

Fibronectin Contributes to Pathological Cardiac Hypertrophy but Not Physiological Growth

Basic Research in Cardiology
Cardiovascular MedicinePhysiologyCardiology
2013English

Role of Interferon Regulatory Factor 4 in the Regulation of Pathological Cardiac Hypertrophy

Hypertension
Internal Medicine
2013English

Tom70 Serves as a Molecular Switch to Determine Pathological Cardiac Hypertrophy

Cell Research
Cell BiologyMolecular Biology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy